Article
Trends in Clinical Development for PD-1/PD-L1 Inhibitors
Article reprint from Nature Reviews Drug Discovery
Apr 17, 2020
  • Library
  • Trends in Clinical Development for PD-1/PD-L1 Inhibitors

Get instant access

Download

This March 2020 article in Nature Reviews Drug Discovery outlines trends in the current landscape of clinical trials evaluating PD-1/PD-L1-targeted monoclonal antibodies, which are now the standard of care for 16 different types of cancer and tissue-agnostic indications. IQVIA and Cancer Research Institute collaborated on the analyses and report.

You may also be interested in

Blog
From Emerging Signals to Smarter Decisions
Blog
What patient behavior reveals about rural access
Solution
Japan Medical Device Regulatory Consulting (DMAH & Shonin)
Blog
MedTech Expert Insights: Navigating Clinical Evidence Challenges in Digital Health
Blog
MedTech Expert Insights: Overcoming Regulatory Challenges in Digital Health and AI
Event/Webinar
From data access to trusted answers: making scientific content AI-ready

Related solutions

Oncology & Hematology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us